Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In atrial fibrillation patients,anticoagulant therapy with warfarin has an excellent stroke preventive. Meantime,Warfarin may also increase the risk of hemorrhagic events. Considering this,warfarin is a drug which puts a great burden on patients and medical providers.
With the population aging, the number of non-valvular atrial fibrillation patients is increasing, and a necessity that not only specialist but also general practitioners. Anticoagulant therapy with warfarin is not easy for general practitioners and is not commonly used among general practioners. In such circumstances, Rivaroxaban,a new oral direct factor Xa inhibitor,has become available. Rivaroxaban is administrated once a day and exert an anti- coagulant effect soon after administration. It hardly reacts with foods or other drugs and therefore does not require regular monitoring. GENERAL study is to investigate the effectiveness of stroke and systemic embolism in non-valvular atrial fibrillation patients when it is prescribed by general practioners in real life settings.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Composite of symptomatic stroke (ischemic/hemorrhagic) and systemic embolism | up to 1.5 years(max 3 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Major bleeding events (adapted ISTH standard) | up to 1.5 years(max 3 years) | |
| Non-major bleeding events(without Major Bleeding complications) | up to 1.5 years(max 3 years) | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
5,000
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Saburo Saito | Contact | +81-6-6872-0010 | general@jcvrf.jp |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Japan Cardiovascular Research Foundation | Recruiting | Suita | Osaka | 565-8565 | Japan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38909144 | Derived | Matsui K, Kusano K, Akao M, Tsuji H, Hiramitsu S, Hatori Y, Odakura H, Ogawa H. Observational study of frailty in older Japanese patients with non-valvular atrial fibrillation receiving anticoagulation therapy. Sci Rep. 2024 Jun 22;14(1):14423. doi: 10.1038/s41598-024-65237-4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
| Composite of symptomatic stroke(ischemic or hemorrhagic),systemic embolism,myocardial infarction/unstable angina pectoris and cardiovascular death |
| up to 1.5 years(max 3 years) |
| Symptomatic stroke (ischemic or hemorrhagic) | up to 1.5 years(max 3 years) |
| Symptomatic ischemic stroke | up to 1.5 years(max 3 years) |
| Symptomatic hemorrhagic stroke | up to 1.5 years(max 3 years) |
| Systemic embolism | up to 1.5 years(max 3 years) |
| Acute myocardial infarction/unstable angina pectoris | up to 1.5 years(max 3 years) |
| Cardiovascular death | up to 1.5 years(max 3 years) |
| Deep vein thrombosis/pulmonary thromboembolism | up to 1.5 years(max 3 years) |
| Transient ischemic attack | up to 1.5 years(max 3 years) |
| Percutaneous coronary intervention /coronary artery bypass grafting | up to 1.5 years(max 3 years) |
| All cause death | up to 1.5 years(max 3 years) |
| Comparison of primary outcome (composite of symptomatic stroke(ischemic/hemorrhagic) and systemic embolism) rate and Major Bleeding complications (adapted ISTH standard)rate between EXPAND study and FUSHIMI AF registry | up to 1.5 years(max 3 years) |
| Adverse Event excluding hemorrhagic events | up to 1.5 years(max 3 years) |
| Patients adherence related with stroke or systemic embolism | up to 1.5 years(max 3 years) |
| Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban | up to 1.5 years(max 3 years) |
| D013568 |
| Pathological Conditions, Signs and Symptoms |